Paper Details

  1. Home
  2. Paper Details

Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.

Author: ChenChengjuan, LiuJiakuo, WangDongmei, ZhangJie, ZhangTiantai

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes the recent progress in the research and development of Bruton's tyrosine kinase (BTK) inhibitors, focusing on structural characteristics and structure-activity relationships. The study analyzes the structure-refinement process of representative pharmacophores and their effects on binding affinity, biological activity, and pharmacokinetics. The advantages and disadvantages of reversible/irreversible BTK inhibitors and their potential implications are discussed to provide a reference for the rational design and development of novel potent BTK inhibitors.
Paper Details　
Original Abstract of the Article :
Therapy based on Bruton's tyrosine kinase (BTK) inhibitors one of the major treatment options currently recommended for lymphoma patients. The first generation of BTK inhibitor, Ibrutinib, achieved remarkable progress in the treatment of B-cell malignancies, but still has problems with drug-resistan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejmech.2021.113329

データ提供：米国国立医学図書館（NLM）

Targeting Bruton's Tyrosine Kinase (BTK): A New Frontier in Lymphoma Treatment

The field of cancer therapy is constantly evolving, with new targets and approaches being explored to improve treatment outcomes. This research reviews the development of small-molecule inhibitors of Bruton's tyrosine kinase (BTK), an important enzyme implicated in lymphoma development. The study highlights the progress in developing new BTK inhibitors, focusing on their structural characteristics and structure-activity relationships.

BTK Inhibitors: A Promising New Approach in Lymphoma Therapy

This review provides a comprehensive overview of the exciting advancements in the development of BTK inhibitors, a novel class of drugs showing promise in treating lymphoma. The researchers highlight the progress made since the introduction of the first-generation BTK inhibitor, Ibrutinib, and discuss the potential of newer, more targeted inhibitors to overcome the challenges of drug resistance and off-target side effects. The study emphasizes the importance of ongoing research and development in this area.

Precision Medicine: Tailoring Treatment to Individual Needs

This review highlights the growing field of precision medicine, where treatments are tailored to individual patients based on their specific genetic and molecular profiles. The development of targeted therapies like BTK inhibitors exemplifies this approach, offering hope for more effective and personalized treatment options for patients with lymphoma.

Dr.Camel's Conclusion

This review is like a treasure map leading us to a promising new frontier in lymphoma treatment. The development of BTK inhibitors represents a significant advancement, demonstrating the potential of precision medicine to revolutionize cancer care. As researchers continue to explore this exciting field, we can anticipate a future where treatments are more effective, personalized, and tailored to the unique needs of each individual patient.

Date :
  1. Date Completed 2021-07-15
  2. Date Revised 2021-07-15
Further Info :

Pubmed ID

33740548

DOI: Digital Object Identifier

10.1016/j.ejmech.2021.113329

Related Literature

Article Analysis
・Side Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.